Mast Therapeutics (MSTX) Reports In-Line Q4 Loss

Mast Therapeutics (NYSE: MSTX) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cintas beats estimates but stock edges lower
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)